The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 14, 2023

Filed:

Nov. 10, 2017
Applicant:

Csl Behring Lengnau Ag, Lengnau, CH;

Inventors:

Stefan Schulte, Marburg, DE;

Thomas Weimer, Gladenbach, DE;

Sabine Pestel, Marburg, DE;

Hubert Metzner, Marburg, DE;

Steve Dower, Fitzroy North, AU;

Assignee:

CSL BEHRING LENGNAU AG, Lengnau, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/755 (2006.01); A61P 7/04 (2006.01); A61K 9/00 (2006.01); A61K 38/37 (2006.01); C07K 14/765 (2006.01); A61K 38/36 (2006.01);
U.S. Cl.
CPC ...
C07K 14/755 (2013.01); A61K 9/0019 (2013.01); A61K 38/36 (2013.01); A61K 38/37 (2013.01); A61P 7/04 (2018.01); C07K 14/765 (2013.01); A61K 2300/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01);
Abstract

The invention pertains to a polypeptide comprising a truncated von Willebrand Factor (VWF) and a half-life extending moiety, for use in the treatment of a blood coagulation disorder, said treatment comprising administering the polypeptide to a subject having a blood coagulation disorder and having endogenous Factor VIII (FVIII), wherein the activity level of endogenous FVIII in said subject before treatment with said polypeptide is reduced relative to the activity level of FVIII in normal human plasma (NHP) provided that the activity level of endogenous FVIII in said subject is at least 0.5% of the activity level of endogenous FVIII in normal human plasma (NHP), wherein the polypeptide is capable of binding to endogenous FVIII and wherein the endogenous FVIII level is increased following administration of said polypeptide.


Find Patent Forward Citations

Loading…